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 Gastrointestinal (GI) tract perforations and obstructions are relatively frequent surgical 
emergencies, are potentially life-threatening, and can occur from several different sources. In 
general, treatment requires urgent surgical repair or resection and at times can lead to further 
complications. Currently available stents are non-absorbable, are manufactured in a narrow size 
range, and/or are limited to usage in locations that are accessible for endoscopic removal post-
healing. The use of 3D-printed bioresorbable polymeric stents will provide patients with a stent 
that can prevent leakage, is tailored specifically to their geometry, will degrade with time to 
eliminate the need for further surgeries for stent removal post-healing, and will be usable in 
locations that are not endoscopically accessible. This project focused on the characterization of 
polycaprolactone-polydioxanone (PCL-PDO) composites for use in a bioresorbable 
gastrointestinal stent. Dynamic Mechanical Analysis (DMA) tests were conducted to separately 
analyze the effects of composition, the filament formation process, and physiological 
temperature on the PCL-PDO material properties. The proposed stent design was then modelled 
using computer-aided design, and Finite Element Analysis (FEA) was used to simulate the 
effects of physiologically relevant forces on stent integrity. The presence of hydrolysable ester 
bonds was confirmed using FTIR spectroscopy, and composite morphology was examined with 
scanning electron microscopy. In vitro studies were used to evaluate the biocompatibility of the 
polymer composite, finding that the PCL:PDO filament had no negative impact on cell viability 
over a period of 48 hours, and in fact was conducive to cell proliferation over a period of 3 days. 
PCL-PDO stents were then 3D-printed and placed in vivo in a pig model, and histological 
evaluation was used to determine the safety of these stents. Further analyses were conducted 
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CHAPTER 1: INTRODUCTION 
1.1 Case study 
 This project came about as a result of a patient case that occurred at Carle Foundation 
Hospital in Urbana, IL. A patient underwent a sleeve gastrectomy, a standard weight loss 
procedure in which a portion of a patient’s stomach is removed to reduce stomach size. As a 
result of this procedure, the patient developed a small bowel obstruction. An attempt to clear this 
obstruction led to the occurrence of gastrointestinal tract leakage, which led to a range of 
complications. As a result, the patient underwent 6 major surgical procedures, 6 inpatient 
hospitalizations, 3 rehab hospitalizations, 5 invasive radiology procedures, and 19 CT scans. Had 
the gastrointestinal tract leakage been prevented when the small bowel obstruction was being 
cleared, the patient would not have undergone such a long list of medical interventions.  
1.2 Small Bowel Perforations & Intestinal Anastomoses 
 Small bowel perforations can result from a number of causes, including small bowel 
obstructions [1]. One commonly used treatment approach is the surgical resection of the 
perforated segment of the small bowel [1]. This involves removal of the diseased portion of the 
small bowel, after which the two ends of the remaining healthy tissues are anastomosed. 
Anastomotic surgeries involve the connection of tissues, and require the use of sutures or staples 
for closure. Patients undergoing such procedures face the risk of anastomotic leakage and/or 
infection. In a study of 1223 patients who had undergone intestinal anastomosis, Hyman et al. 
found that 2.7% of these patients experienced anastomotic leakage [2]. In similar studies, Tan et 
al. found that 3.6% of 504 patients who had undergone colorectal anastomosis experienced 
anastomotic leakage [3], while Hammond et al. found that 6.18% of 6,174 colorectal 
anastomosis patients experienced leakage [4].  
 Anastomotic leakages can be costly, with a reported mortality rate ranging from 10 to 
15% [2] and an estimated additional cost of $28.6 million per 1,000 patients who undergo 
colorectal surgery  [4]. Infection is another cause for concern in surgeries involving the use of 
sutures or staples. Both sutures and staples have been found to lead to infections when used in 
various surgical applications [5], [6]. Thomson et al. used tissue phantoms and finite element 
analysis to show that tension in sutures could result in leakage areas of up to 0.1 mm2, a large 
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enough area to allow for the passage of some common types of bacteria [7]. Thus, the occurrence 
of infection can be related to the occurrence of anastomotic leakage. This is further supported by 
clinical results such as those found by Hammond et al., which indicate that colorectal 
anastomosis patients who experienced leakage were 0.8 to 1.9 times as likely to have infections 
than patients who did not have anastomotic leakage. Such infections can potentially lead to the 
development of sepsis, which was the cause of 17% of hospital deaths in 2008 alone [8].  
 
1.3 Current Solutions  
 A number of strategies can be utilized in order to combat the infection and leakages 
caused by surgical sutures and staples. For example, a variety of stapling techniques have been 
examined in a porcine model, finding that techniques such as side to side anastomosis with a 
linear stapler and side to side anastomosis with a circular stapler can result in increased burst 
pressure compared to other methods [9]. Other strategies have looked at reducing biofilm 
buildup through surface modification, specifically the use of plasma to generate nanostructured 
topographies that effect bacterial adhesion, finding that in some cases exposure of sutures to 
plasma significantly reduced bacterial adhesion [10]. More commonly, commercially available 
surgical sealants such as Coseal, FloSeal, and other sealants have been successfully used in 
addition to sutures and/or staples in order to reduce infection and blood loss during surgery [11]–
[14]. Despite their effectiveness, many of these products face drawbacks such as a lack of 
adhesive strength or biocompatibility[15].  
 
 For gastrointestinal applications in particular, there are currently a number of 
commercially available tools for endoscopic intervention[16]. Expandable metal stents can be 
used to treat gastrointestinal tract obstructions. These include esophageal stents, duodenal stents, 
biliary stents, and colorectal stents, and can be delivered endoscopically [17]. However, these 
stents would not degrade due to their metallic nature, and cannot aid in preventing leakage as 
they are made of a mesh structure with many holes. Additionally, endoscopic procedures 
themselves can sometimes cause some complications, including causing perforations, leakage, 
and fistulas[16]. Some other endoscopic techniques, such as the Over-The-Scope Clip (OTSC®) 
system exist to specifically treat perforations with clips. These techniques have their own 
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limitations, such as requiring a large diameter for the endoscope and clip to be able to pass 
through the intestines[16].  
 
1.4 Design Requirements 
 An ideal solution would incorporate a biodegradable stent which can be placed during 
small bowel resection. Such a stent would not require endoscopic placement or removal, would 
degrade with time, and would prevent leakage from the interface between the two segments of 
healthy intestinal tissue.  
1.5 Proposed Approach 
 The goal of this project was to develop a customizable bioresorbable gastrointestinal stent 
that could be rapidly fabricated for clinical use (Fig. 1.1). In particular, 3D printing has shown 
promise as a rapid manufacturing method for medical applications[18]–[20]. The stent utilizes a 
polymer composite formed by two FDA-approved biodegradable polymers. The polymer 
composite is formed into a filament which can be used in a commercially available 3D-printer to 
print a stent with the desired dimensions. Stent dimensions are determined based on CT imaging 
of the patient geometry, and a 3D computer model is generated based on these dimensions. The 
computer model can then be 3D-printed with the polymer composite, forming a customized 




Figure 1.1. Stent production process. Biodegradable polymers are used to create a 3D-printing filament. CT 
imaging is used to determine the desired stent dimensions, and a computer model of the stent is created based on 
these dimensions. The filament and computer model are then used to 3D-print a customized stent.  
 When a segment of an intestine is resected, the two ends of the remaining healthy tissue 
will be connected over this stent (Fig. 1.2). The stent will prevent the occurrence of leakage at 
the interface between the two intestinal segments, and will degrade over time to eliminate the 
need for removal post-healing.    
1.6 Polycaprolactone & Polydioxanone 
Polycaprolactone (Fig. 1.3 A) and Polydioxanone (Fig 1.3 B), both of which are FDA-approved 
polymers, were selected due to their biocompatibility, biodegradability, and proven track record 
in biomedical applications. Polycaprolactone is commonly used for applications in drug delivery 
and cell scaffolding [21]–[26]. Polydioxanone is well-known for use in surgical sutures and 






Figure 1.2 Proposed Stent Placement (a) A gastrointestinal tract occlusion or hole is detected. (b) The occlusion is 
surgically removed. (c) A biodegradable stent is placed in the remaining healthy intestinal tissue. (d) The ends of the 
healthy tissue are attached to each other. (e)  The ends of the healthy tissue remain attached and the stent degrades 
with time, allowing the healthy tissue segments to heal.  
       





CHAPTER 2: MATERIALS & METHODS 
2.1 Materials 
 Poly(caprolactone) (50,000 MW) was purchased from Polysciences, Inc. 
Poly(dioxanone) was purchased from Evonik Inc. 1,1,1, 3, 3, 3, Hexafluoro-2-propanol (HFP) 
and 2,2’ Trifluoroethanol (TFE) were purchased from Sigma Aldrich and Alfa Aesar 
respectively. Calcium chloride was obtained from Sigma-Aldrich. Fresh whole pig blood was 
collected from the UIUC Meat Science Lab in citrate anticoagulant-treated tubes. 
2.2 Polymer Composite Formation 
 Polymer composites were formed by dissolving varying mass ratios of PCL and PDO in 
HFP or TFE. Each polymer was separately dissolved into the solvent (HFP or TFE) at a 
concentration of 8 mg/mL, and the solutions were then mixed and allowed to stir on a stir plate. 
Five different compositions were synthesized (Table 2.1). 
Table 2.1 Various PCL:PDO compositions synthesized 
Composition Name PCL content [% by mass] PDO content [% by mass] 
PCL 100 0 
75:25 PCL:PDO 75 25 
50:50 PCL:PDO 50 50 
25:75 PCL:PDO 25 75 
PDO 0 100 
 
 The composites were dried on a rotary evaporator under vacuum at a temperature of 50-
90 ˚C. In order to dry large quantities of the composite at a time, a custom-made flask (Fig. 2.1) 
was obtained from the UIUC glass shop. This allowed for the drying of 200-250 mL of the 
composite solution over a period of approximately 1-2 hours. Samples were left in a vacuum 




Figure 2.1. Custom-made flask for polymer composite drying. 200-250 mL of the polymer composite sample is 
added to the base. An O-ring is then inserted between the base and removable top section, and the removable top is 
added above the o-ring. A horseshoe clamp is then fastened to secure the connection between the top and base.  
2.3 Filament Formation 
 The dried polymer composite was cut into small pellets to be used in filament formation 
(Figure 2.2).  
 
Figure 2.2: Polymer composite processing. The composite was shredded into small pellets, which were then 
extruded into the filament. The filament was utilized in a 3D-printer to obtain 3D printed stents.  
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 Preliminary experiments were conducted using the Filastruder (Fig. 2.3 A). The filaments 
were formed at temperatures ranging from 90 to 100 ˚C, with an extrusion diameter of 2 mm. 
The Filabot (Fig. 2.3 B) was used for all further experiments. For Filabot extrusion, highest 
extrusion success was found when the temperature was initially set to approximately 125 ˚C, 
after which it was lowered in intervals of 5-10 degrees to 90 ˚C and the extrusion process was 
completed. An extrusion diameter of 1.75 mm was used.  
 
Figure 2.3: Filament Extruders. (A) Filastruder. (B) Filabot. Both extruders utilize a motor and screw to push the 
material forward towards a heated extruder tip. The material melts at the tip, and is pushed out in the form of a 
cylindrical filament.  
2.4 Film Formation 
 Films for mechanical testing were formed by pouring 2 mL of the undried polymer 
composite into glass bottles with a diameter of approximately 2.5 cm. The composites were then 
allowed to dry in a vacuum dessicator, forming a porous film (Fig. 2.4 A-B).  
2.5 Dynamic Mechanical Analysis (DMA) 
 Dynamic Mechanical Analysis testing was conducted in tension on a Q800 DMA at a 
force ramp of 1 N/minute with a maximum force of 18 N and a preload force of 0.001 N. 
Dynamic mechanical analysis was conducted on PCL, PCL:PDO 75:25, PCL:PDO 50:50, 
PCL:PDO 25:75, and PDO rectangular film samples cut from the dried composite (Fig. 2.4 C). 
Sample thickness, length, and width were recorded prior to testing. PCL:PDO 25:75 filament 
extruded with the Filastruder were tested  at both room temperature and a temperature of 37 ˚C. 
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Filament length and diameter were recorded prior to testing. All tests were conducted in 
triplicate.  
 The slope of the linear portion of the stress-strain curves was used to calculate the 
modulus of elasticity (E). The yield stress was calculated by drawing a line of slope E with an 
initial 0.2% strain offset, and locating its point of intersection with the stress-strain curve.  
  
Figure 2.4. Film samples and dynamic mechanical analysis. (A) Round film sample. (B) Rectangular film 
samples used for dynamic mechanical analysis. (C) Dynamic mechanical analysis on a film sample. Inset depicts 
failed film sample.  
2.6 Computer Aided Design (CAD) & Finite Element Analysis (FEA) 
 CAD and FEA were conducted in Creo Parametric. The stents were modelled as thin-
walled cylinders of various designs, with minimum outer diameters of 30 mm and varying 
thicknesses and geometries. The designs also incorporated 4 equally-spaced 1 mm-diameter 
holes on each end to allow for suture placement. For FEA, a modulus of elasticity of 211 MPa 
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was incorporated into the model based on the results of DMA experiments. The 4 holes on each 
end of the stent were constrained as having fixed positions, and an internal pressure of 1765 Pa 
was applied to each stent. This pressure was determined by taking the internal pressure reported 
by Fink [30], and doubling it to incorporate a safety factor of 2. These parameters are 
summarized in Table 2.2.  
Table 2.2 Parameters used for FEA study 
Modulus of Elasticity 211 MPa 
Applied Pressure 1765 Pa 
Boundary Conditions Hole positions fixed 
 
2.7 Scanning Electron Microscopy (SEM)  
 SEM images of the PCL:PDO 25:75 film samples were taken. Samples were coated with 
gold-palladium before imaging with a JEOL 6060 Scanning Electron Microscope with an 
acceleration voltage of 5 kV.  
2.8 3D printing 
 Preliminary 3D printing was conducted using an Airwolf 3D HD printer at temperatures 
ranging from 180 ˚C to 220 ˚C. For the degradation and in vivo studies, the Dremel 3D printer at 
the UIUC MakerLab was used with an extrusion temperature of 180 ˚C. An Ultimaker 3D printer 
at the UIUC MakerLab was used for ex vivo stent placement experiments.  
2.9 FTIR 
 FTIR measurements were taken for PCL, PDO, the 25:75 PCL:PDO composite, and the 
25:75 PCL:PDO filament. Measurements were taken using ATR-FTIR on a Thermo Nicolet 
Nexus 670 FT-IR. Samples were compressed into compacted disks prior to FTIR measurement.  
2.10 Cell Viability & Proliferation 
 Cell viability was assessed for ATCC® CRL-7820™ human intestinal cells grown in an 
A592 24-well plate (60,000 cells per well). Cells were exposed to the material of interest (PCL, 
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PDO, 25:75 PCL:PDO composite, or 25:75 PCL:PDO filament) for 48 hours. Each test was 
conducted in triplicate, and for varying masses of the material (10 mg and 100 mg). An MTT 
assay was used to measure cell metabolic activity after 48 hours, and cells were imaged with a 
Leica DMI 3000 B optical microscope for observation of morphological changes. The % cell 
viability was calculated as follows: 
% 𝑐𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
𝐴592 𝑠𝑎𝑚𝑝𝑙𝑒 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 − 𝐴592 𝑏𝑙𝑎𝑛𝑘
𝐴592 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 − 𝐴592 𝑏𝑙𝑎𝑛𝑘
∗ 100% 
 After incubation with cells, samples were allowed to soak in deionized water for 1 hour, 
followed by drying in a vacuum oven. Samples were then weighed to calculate the mass as a 
percentage of the initial mass. A change in sample weight would provide insight into cell-sample 





 The ability of the materials to alter the cell attachment and survival properties was 
assessed after exposure of the cells to the materials for 3 days. As before, the tests were 
conducted in triplicate for varying masses of the materials (10 mg and 100 mg), viability was 
measured using an MTT assay, and samples were weighed after incubation and washing.  
2.11 Blood Smear 
 Blood smear experiments were conducted by exposing 150 µL of whole fresh pig blood 
to 25 mg of PCL, PDO, PCL:PDO 25:75 composite, PCL:PDO 25:75 filament, or to 0.025 M 
calcium chloride solution. Experiments were conducted in triplicate. The blood was smeared 
onto glass slides after 15 minutes of exposure to the material of interest, and optical microscopy 
images were taken with a Leica DMI 3000 B. 
2.12 Assessment of Safety  
 A preliminary animal study was conducted in two pigs. The animals were imaged with 
16-slice Computed Tomography (CT) imaging, small intestine dimensions were obtained based 
on these images, and the stent models were generated based on these dimensions. One animal 
was used as a control, in which the stent dimensions were smaller than the dimensions 
12 
 
determined by imaging, and the other animal was used as the experimental animal, in which the 
stent dimensions matched those of the animal. A cylindrical stent with a length of 1 cm and 
thickness of 1 mm was printed for each animal.  
 The animals were anesthetized, after which an abdominal incision was made, the small 
intestine was accessed, and an intestinal incision was made. The ends of the small intestine were 
then reattached over the stents, and the stents were sutured in place. The animals were allowed to 
survive for two weeks, or until they experienced complications as a result of the operation.  
2.13 Placement In ex vivo Intestines 
 Multiple stent designs were evaluated through ex vivo placement in stent intestines. The 
ex vivo intestines were cut and measured, and stents were 3D-printed using a Poly(lactic acid) 
(PLA) filament. The stents were then sutured in place in the ex vivo intestines, and observations 
on the ease of placement and the security of the fit were recorded.  
2.14 Statistical Analysis 




CHAPTER 3: MECHANICAL & PHYSICAL CHARACTERIZATION 
3.1 Dynamic Mechanical Analysis (DMA) 
 Representative stress-strain curves for film samples of each composition are given in Fig. 
3.1 A. Based on these curves, the modulus of elasticity (Fig. 3.1 B) is found to increase with 
PDO content in the PCL:PDO composites. PDO alone exhibits a slightly lower modulus than the 
25:75 PCL:PDO ratio, but this is not statistically significant. The yield strength (Fig. 3.1 C) of 
the 25:75 PCL:PDO composition was found to be lower than that of the 75:25 PCL:PDO 
composition. Despite this, the 25:75 PCL:PDO ratio has a high yield strength of approximately 2 
MPa. As a result, the 25:75 PCL:PDO ratio was chosen for further analysis.  
 Representative stress-strain curves and calculated moduli of elasticity are shown in Fig 
3.2. The 25:75 PCL:PDO composite was found to have a slight increase in modulus of elasticity 
as a result of filament formation. This was likely due to a reduction in composite porosity as a 
result of filament formation. The presence of pores in a sample would lead to a true cross-
sectional area that is lower than the actual cross-sectional area, leading to a lower calculated 
stress than the true stress value. The increase in temperature from room temperature to 
physiological temperature did not lead to any statistically significant change in the modulus of 






Figure 3.1: Mechanical Analysis of Film samples. (A) Representative stress-strain curves for each composition. 
Inset depicts linear region used for calculation of modulus of elasticity. (B) Average modulus of elasticity for each 
composition. The 25:75 PCL:PDO ratio exhibits the highest modulus, with modulus generally increasing with 
increased PDO content. Double asterisks indicate statistical significance with α ≤ 0.05.  Single asterisks indicate 
statistical significance with α ≤ 0.11. Error bars represent standard error. (C) Average yield strength for each 
composition. The 25:75 PCL:PDO ratio exhibits lower yield strength than the 75:25 PCL:PDO composition. Double 
asterisks indicate statistical significance with α ≤ 0.01. n=3 for all samples except PDO, for which n=2 as one 
sample did not yield.  




Figure 3.2: Mechanical Analysis of 25:75 PCL:PDO Filaments. (A) Representative stress-strain curves for 
filaments tested at room temperature and at physiological temperature. (B) Average modulus of elasticity for 
filaments tested at room temperature and at physiological temperature. Temperature change did not lead to a 
statistically significant change in modulus.     
3.2 Finite Element Analysis (FEA) 
 Finite element analysis was conducted for 3 different designs (Fig. 3.3). The cylindrical 
design was a simple thin-walled cylinder with a constant inner and outer diameter. The 
reinforced cylindrical design incorporated rims at the two ends of the stent. These rims would 
double the thickness in the rimmed areas compared to the unrimmed areas, while the inner 
diameter remained unchanged.  The third design was a curved design, in which both the inner 
and outer diameters increased from their minimum values at the center of the stent to their 
maximum values at the two ends of the stent, with the thickness remaining constant throughout. 
A length of 60 mm and a minimum outer diameter of 30 mm were maintained for all designs. 
Four different stent thicknesses were evaluated for each design (1 mm, 0.75 mm, 0.5 mm, 0.25 




Figure 3.3. Three proposed stent designs used in FEA analysis 




Inner Diameter [mm] Outer Diameter [mm] 
Min Max Min Max 
Cylindrical 
1 28 28 30 30 
0.75 28.5 28.5 30 30 
0.5 29 29 30 30 
0.25 29.5 29.5 30 30 
Reinforced 
1 28 28 30 32 
0.75 28.5 28.5 30 31.5 
0.5 29 29 30 31 
0.25 29.5 29.5 30 30.5 
Curved 
1 28 30 30 32 
0.75 28.5 30 30 31.5 
0.5 29 30 30 31 
0.25 29.5 30 30 30.5 
 
 The applied pressure and constraints on an example stent is shown in Figure 3.4 A. The 
maximum stent deformation and the maximum stress experienced by the stent are shown in 
Figure 3.4 B-C. The cylindrical and curved designs experienced comparable deformation and 
stress, while the reinforced cylindrical design exhibited the least deformation and stress. As 
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expected, the maximum deformation and maximum stress were found to be inversely 
proportional to the stent thickness, with a thinner stent leading to higher stress and deformation. 
Despite this, the maximum deformation observed was less than 0.02 mm, and the maximum 
stress observed was less than 0.4 MPa. Due to the material having a yield strength of 
approximately 2 MPa, and having already incorporated a safety factor of 2 when applying the 





Figure 3.4. FEA Analysis Results. (A) Applied Pressure and motion constraints on a model stent. The green arrows 
indicate the uniformly distributed applied internal pressure. The blue markings indicate the suture holes which were 
constrained to remain in fixed positions. The orange tag indicates the assigned material properties based on the 
25:75 PCL:PDO filament properties. (B) Maximum deformation as a function of stent design and thickness. The 
reinforced cylindrical design experienced the least deformation. (C) Maximum Stress as a function of stent design 
and thickness. The reinforced cylindrical design experienced the lowest maximum stress.  
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 The location of maximum deformation was also found to vary based on stent design (Fig 
3.5). The cylindrical and curved designs each had their maximum deformation at the stent edges, 
equidistant from adjacent suture holes. The reinforced cylindrical design, however, had its 
maximum deformation shifted closer to the center of the stent, due to the addition of the rim at 
the stent edges. This provides insight into where the expected location of failure for each design 
would be. Should the stents fail, a failure at the outer edges of the stents may not be as 
catastrophic as a failure closer to the center of the stent, as the center of the stent would be 
closest to the site of the original incision, and thus more likely to cause leakage into the body. 
Thus, the cylindrical and curved designs may be better suited for this application than the 
reinforced cylindrical design.  
 
Figure 3.5. Locations of minimum and maximum deformation for each stent design. The cylindrical and curved 
designs exhibit maximum deformation at stent edges, while the reinforced cylindrical design displays a shift in 
maximum deformation closer to the center of the stent. Scale units are in mm.  
3.3 Scanning Electron Microscopy (SEM)  
 SEM images of the film samples showed a porous structure with uniform mixing of the 
polymer (Fig. 3.6). This further supports the idea that the increase in modulus of elasticity of the 




Figure 3.6. Scanning electron microscopy images of the 25:75 PCL: PDO film. Images show a uniformly mixed 
porous surface. 
3.4 FTIR 
 FTIR was used to confirm the presence of both PCL and PDO in the composite and 
filament (Figure 3.7). The sharp peak near 1720 cm
-1
 in PCL and 1735 cm
-1
 in PDO can be 
attributed to the C=O from the ester bonds in these polymers [31], [32]. The presence of sharp 
peaks in this range for both the PCL:PDO composite and PCL:PDO filament indicate that the 
ester bonds were preserved after composite and filament formation. This is important because the 
degradation mechanism for these polymers is the hydrolysis of their ester bonds.  
 
Figure 3.7. FTIR spectra for the polymers, composite, and filament. Characteristic C=O peak (black arrow) 




CHAPTER 4: IN VITRO CHARACTERIZATION 
4.1 Cell Viability 
 When exposed to a low mass (10 mg) of the materials, human intestinal cells did not 
show any significant change in metabolic activity (Fig. 4.1 A). However, when exposed to a 
higher mass (100 mg) of the materials, the PCL, PDO, and composite all appeared to induce a 
reduction in cell metabolic activity, indicating possible cytotoxic effects. Despite this, the 
filament was still found to have cell metabolic activity that was comparable to the control, even 
at the higher dose. An increase in material dose was also found to lead to decreases in cell 
density and morphological deformations for cells exposed to PCL, PDO, and the composite (Fig. 
4.2). These adverse effects were not observed in the control cells or the cells exposed to the 
filament. 
 The low cytotoxicity of the filament compared to the raw materials and composite may 
have been due to the high temperature exerted on the material during the filament extrusion 
process, which may have led to the death of contaminants that existed in the raw materials or 
composite. This low cytotoxicity may have also been caused by a difference in the materials’ 
surface area exposed to the cells, which may have varied as a result of shape, with the filament 
having a cylindrical shape while the composite has a porous surface, and the PCL and PDO 
taking the form of beads and pellets respectively. The materials themselves did not show a 
change in mass after exposure to the cells (Fig. 4.1 B), indicating that cells were not seeded 





Figure 4.1. Cell Viability determined from metabolic activity of human intestinal cells exposed to various 
concentrations of the polymer, composite, or filament. (A) The filament shows high viability even for a high 
mass, while the PCL alone, PDO alone, and composite show a decrease in cell viability for higher doses of material. 
Error bars represent standard deviation. Single asterisks indicate statistical significance with α ≤ 0.05. Double 
asterisks indicate statistical significance with α ≤ 0.01. (B) Sample weight after exposure to cells and being washed. 
No statistically significant changes were observed. Values are expressed as percent of the initial weight for each 




Figure 4.2. Optical microscopy of cells exposed to the polymers, composite, and filament. White arrows 
indicate deformations in cell morphology, and black arrows indicate low cell density. Higher doses of the materials 




4.2 Cell proliferation 
 The filament was both found to be conducive to cell proliferation over a period of 3 days, 
while PCL and PDO alone were not (Fig. 4.3 A). For the filament, cell proliferation was found to 
increase with dose. PCL and PDO alone were found to cause a reduction in cell proliferation. 
These results suggest that the filament can provide a surface on which cells can grow and 
proliferate, potentially aiding in healing the intestinal segments after stent placement.  Despite 
providing a surface that was conducive to cell growth, the filament did not show any significant 
changes in weight after exposure to the cells (Fig. 4.3 B), indicating that the cellular material did 
not penetrate the samples, and was easily removed via washing of the samples.   
Figure 4.3. Cell proliferation determined from metabolic activity of human intestinal cells exposed to various 
concentrations of the polymer, composite, or filament. (A) Cell viability for cells grown on the materials. At 
the low concentration, PCL and PDO reduce cell viability, while the filament increases cell viability. At the high 
concentration, the filament increased cell viability. Error bars represent standard deviation. Single asterisks indicate 
statistical significance with α ≤ 0.1. Double asterisks indicate statistical significance with α ≤ 0.05. (B) Sample 
weight after exposure to cells and being washed. No statistically significant changes were observed. Values are 
expressed as percent of the initial weight for each sample. Error bars represent standard deviation.  
4.3 Blood Smear 
 The exposure of blood to the polymers, composite, and filament did not appear to cause 
any adverse effects in blood cell morphology (Fig. 4.4). This indicates that these materials will 










CHAPTER 5: IN VIVO PLACEMENT 
5.1 Assessment of Safety  
 CT images of the pigs were successfully obtained and used to identify small and large 
intestine dimensions for the animals (Fig. 5.1). The 3D models were generated based on the 
measured small intestine dimensions.  
 
Figure 5.1 CT images of pigs used for in vivo study. Small intestine dimensions are annotated in yellow, and large 
intestine dimensions are annotated in red.  
 The successful completion of the surgical procedure demonstrated the feasibility of 
intestine measurement and stent placement via the proposed procedure. The lack of suture holes 
in the stents used for the in vivo study provided a challenge during stent placement, suggesting 
the importance of suture hole incorporation in the final design. The control animal experienced 
complications within a few days of stent placement, and was sacrificed to prevent further 
suffering of the animal. These complications were likely due to the stent having a smaller 
diameter than that of the pig’s intestine. This reinforces the importance of custom-made stents, as 
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well as the importance of accurate measurements prior to stent fabrication. The experimental pig 
did not show symptoms of complication, and was sacrificed two weeks after stent placement as 
described by the protocol. Histological analysis of tissues from the experimental animal (Table 
5.1) indicated some abnormalities, but histological analysis of tissues from an untreated control 
animal is required for an accurate determination of the cause of histological abnormalities.  
 
Figure 5.2 Placement in ex vivo intestines. An abdominal incision was made and a segment of the small intestine 






Table 5.1 Histology results 
Tissue Observations 
Jejunum Multifocal to coalescing, marked, lymphohistiocytic and eosinophilic enteritis with 
intralesional foreign material and suture granulomas 
Lung Multifocal, moderate, acute pulmonary edema 
Liver Diffuse, mild, acute, vacuolar hepatocellular degeneration 
Kidney Focal, mild, lymphoplasmacytic interstitial nephritis 
Kidney Multifocal, mild, acute tubular degeneration 
Ovary Presumptive follicular amyloidosis 
Duodenum Multifocal, moderate, lymphohistiocytic and eosinophilic duodenitis 
 
5.2 Ex Vivo Placement 
 Based on observations from the in vivo study, the ease of placement for cylindrical, 
cylindrical reinforced, and curved stent designs with incorporated suture holes was evaluated ex 
vivo. The curved design (Fig. 5.3) was found to be the easiest to place without experiencing 
slipping of the intestinal segments. The curvature in this design can potentially allow for a secure 
fit which may reduce risk of passage of intestinal contents between the inside of the intestine and 
the outside of the stent. The ability of this stent to be sutured in place via the suture holes was 





Figure 5.3: Stent placement in ex vivo pig intestines. (A) Incorporation of two intestinal segments over a model 
stent. The stent was 3D-printed with a commercially available material as proof of concept. (B) Evaluation of 
suturing feasibility using holes incorporated into stent design. (C) Demonstration of ability of stent-intestine 




CHAPTER 6: CONCLUSION 
 PCL:PDO composites with varying ratios of PCL and PDO were prepared and 
characterized. Film samples made of the 25:75 PCL:PDO ratio were found to display the highest 
modulus of elasticity, and this ratio was selected for further experiments. Filament samples of the 
25:75 PCL:PDO ratio were found to have a modulus of elasticity of approximately 211 MPa, 
with filaments exhibiting a slightly higher modulus of elasticity than the film samples. SEM 
images showing the porous surface structure of the film samples suggest a change in porosity 
during the filament extrusion process as a possible cause of the increase in modulus of elasticity. 
The presence of the ester C=O bond within the filament indicates retention of the hydrolysable 
ester bond which is essential to composite degradation. Finite element analysis was conducted 
with cylindrical, reinforced cylindrical, and curved designs with a range of stent thicknesses. A 
decrease in stent thickness was found to lead to an increase in the stress and deformation 
experienced by the stent. Despite this, the largest stress experienced by any stent was found to be 
less than 0.4 MPa, well below the yield strength of the material. The maximum deformation 
experienced in FEA models was less than 0.02 mm, and the location of this maximum 
deformation was found to vary based on stent design.  
 At a high dose, PCL and PDO alone were found to have adverse effects on cell viability 
over a period of 48 hours, leading to alteration of cell morphology and a reduction in cell 
density. The composite and filament samples were found to have no negative impact on cell 
viability at the low dose, and the filament samples were found to have no negative impact on cell 
viability even at the higher dose. This suggests that the temperature used in the filament 
extrusion process may have contributed to material sterility. Further experiments conducted over 
a period of three days found that the filament provided a surface that was conducive to cell 
growth, leading to an increase in cell proliferation for both low and high doses. Blood smear 
testing showed no morphological changes in blood as a result of exposure to the materials, 
suggesting the safety of material exposure to blood at the surgical site.  
 In vivo experiments in pigs demonstrated the feasibility of using dimensions derived from 
CT images as a basis for stent fabrication, as well as the feasibility of stent placement via the 
proposed method. The adverse effects observed in the control pig reinforced the importance of 
using custom-made stents for each patient. Ex vivo placement of various stent designs indicated 
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the ease of placement of the curved stent design, as well as the importance of suture holes for 
stent placement. The ability of the stent and intestine combination to retain liquid showed the 
promising potential of these stents to one day serve as a barrier to gastrointestinal tract leakage 
post-surgery.  
 In the future, further in vivo experiments will be conducted in pigs to assess the ability of 
these stents to prevent leakage in the presence of tears within the intestinal tissue lying on the 
outer surface of the stent. Additional experiments will assess the degradation time and in vitro 





[1] D. Lapham and J. Giannone, “Acute Care General Surgery,” pp. 139–145, 2017. 
[2] N. Hyman, T. L. Manchester, T. Osler, B. Burns, and P. a. Cataldo, “Anastomotic Leaks 
After Intestinal Anastomosis,” Ann. Surg., vol. 245, no. 2, pp. 254–258, 2007. 
[3] T. WP, H. EY, P. B, I. GA, and G. SD, “Anastomotic leaks after colorectal anastomosis 
occurring more than 30 days postoperatively: a single-institution evaluation.,” Am Surg, 
vol. 80, no. 9, 2014. 
[4] J. Hammond, S. Lim, Y. Wan, X. Gao, and A. Patkar, “The Burden of Gastrointestinal 
Anastomotic Leaks: An Evaluation of Clinical and Economic Outcomes,” J. Gastrointest. 
Surg., vol. 18, no. 6, pp. 1176–1185, 2014. 
[5] T. O. Smith, D. Sexton, C. Mann, and S. Donell, “Sutures versus staples for skin closure 
in orthopaedic surgery: meta-analysis,” Bmj, vol. 340, no. mar16 1, pp. c1199–c1199, 
2010. 
[6] S. Kobayashi, M. Ito, S. Yamamoto, Y. Kinugasa, M. Kotake, Y. Saida, T. Kobatake, T. 
Yamanaka, N. Saito, and Y. Moriya, “Randomized clinical trial of skin closure by 
subcuticular suture or skin stapling after elective colorectal cancer surgery.,” Br. J. Surg., 
vol. 102, no. 5, pp. 495–500, 2015. 
[7] G. a. Thomson, “An investigation of leakage tracts along stressed suture lines in phantom 
tissue,” Med. Eng. Phys., vol. 29, no. 9, pp. 1030–1034, 2007. 
[8] M. J. Hall, S. N. Williams, C. J. DeFrances, and A. Golosinskiy, “Inpatient care for 
septicemia or sepsis: a challenge for patients and hospitals.,” NCHS Data Brief, no. 62, pp. 
1–8, 2011. 
[9] T. Ikeda, R. Kumashiro, E. Oki, K. Taketani, K. Ando, S. Aishima, T. Akahoshi, M. 
Morita, and Y. Maehara, “Evaluation of techniques to prevent colorectal anastomotic 
leakage,” J. Surg. Res., vol. 194, no. 2, pp. 450–457, 2015. 
[10] C. Serrano, L. García-Fernández, J. P. Fernández-Blázquez, M. Barbeck, S. Ghanaati, R. 
Unger, J. Kirkpatrick, E. Arzt, L. Funk, P. Turón, and A. del Campo, “Nanostructured 
medical sutures with antibacterial properties,” Biomaterials, vol. 52, pp. 291–300, 2015. 
[11] L. J. Garcia-Morales, M. Ramchandani, M. Loebe, M. J. Reardon, B. A. Bruckner, and B. 
Ramlawi, “Intraoperative Surgical Sealant Application during Cardiac Defect Repair,” 
vol. 41, no. 4, pp. 440–442, 2014. 
[12] S. Giuratrabocchetta, M. Rinaldi, F. Cuccia, M. Lemma, D. Piscitelli, P. Polidoro, and D. 
F. Altomare, “Protection of intestinal anastomosis with biological glues: An experimental 
randomized controlled trial,” Tech. Coloproctol., vol. 15, no. 2, pp. 153–158, 2011. 
33 
 
[13] C. Lequaglie, G. Giudice, R. Marasco, A. Della Morte, and M. Gallo, “Use of a sealant to 
prevent prolonged air leaks after lung resection: a prospective randomized study,” J. 
Cardiothorac. Surg., vol. 7, no. 1, p. 106, 2012. 
[14] B. S. Kheirabadi, A. Field-Ridley, R. Pearson, M. MacPhee, W. Drohan, and D. Tuthill, 
“Comparative Study of the Efficacy of the Common Topical Hemostatic Agents with 
Fibrin Sealant in a Rabbit Aortic Anastomosis Model,” J. Surg. Res., vol. 106, no. 1, pp. 
99–107, 2002. 
[15] M. Kazemzadeh-Narbat, N. Annabi, and A. Khademhosseini, “Surgical sealants and high 
strength adhesives,” Mater. Today, vol. 18, no. 4, pp. 176–177, 2015. 
[16] R. Conigliaro and M. Frazzoni, Diagnosis and Endoscopic Management of Digestive 
Diseases. 2017. 
[17] T. H. Baron, “Expandable Metal Stents for the treatment of cancerous obstruction of the 
gastointestinal tract,” New Engl J. Med, vol. 344, no. 22, pp. 1681–1687, 2001. 
[18] C. L. Ventola, “Medical Applications for 3D Printing: Current and Projected Uses.,” P T, 
vol. 39, no. 10, pp. 704–711, 2014. 
[19] R. J. Morrison, S. J. Hollister, M. F. Niedner, M. G. Mahani, a. H. Park, D. K. Mehta, R. 
G. Ohye, and G. E. Green, “Mitigation of tracheobronchomalacia with 3D-printed 
personalized medical devices in pediatric patients,” Sci. Transl. Med., vol. 7, no. 285, pp. 
285ra64–285ra64, 2015. 
[20] N. Sandler, I. Salmela, A. Fallarero, A. Rosling, M. Khajeheian, R. Kolakovic, N. Genina, 
J. Nyman, and P. Vuorela, “Towards fabrication of 3D printed medical devices to prevent 
biofilm formation,” Int. J. Pharm., vol. 459, no. 1–2, pp. 62–64, 2014. 
[21] C. Allen, Y. Yu, D. Maysinger, and A. Eisenberg, “Polycaprolactone-b-poly(ethylene 
oxide) block copolymer micelles as a novel drug delivery vehicle for neurotrophic agents 
FK506 and L-685,818,” Bioconjug. Chem., vol. 9, no. 5, pp. 564–572, 1998. 
[22] T. P. Burton, A. Corcoran, and A. Callanan, “The effect of electrospun polycaprolactone 
scaffold morphology on human kidney epithelial cells,” Biomed. Mater. 
[23] E.-R. Kenawy, F. I. Abdel-Hay, M. H. El-Newehy, and G. E. Wnek, “Processing of 
polymer nanofibers through electrospinning as drug delivery systems,” Mater. Chem. 
Phys., vol. 113, no. 1, pp. 296–302, 2009. 
[24] A. Kumari, S. K. Yadav, and S. C. Yadav, “Biodegradable polymeric nanoparticles based 
drug delivery systems,” Colloids Surfaces B Biointerfaces, vol. 75, no. 1, pp. 1–18, 2010. 
[25] P. S. P. Poh, C. Hege, M. P. Chhaya, E. R. Balmayor, P. Foehr, R. H. Burgkart, J. T. 
Schantz, S. M. Schiller, A. F. Schilling, and D. W. Hutmacher, “Evaluation of 
34 
 
polycaprolactone − poly-D,L-lactide copolymer as biomaterial for breast tissue 
engineering,” Polym. Int., vol. 66, no. 1, pp. 77–84, 2017. 
[26] M. I. Santos, R. E. Unger, R. a. Sousa, R. L. Reis, and C. J. Kirkpatrick, “Crosstalk 
between osteoblasts and endothelial cells co-cultured on a polycaprolactone-starch 
scaffold and the in vitro development of vascularization,” Biomaterials, vol. 30, no. 26, 
pp. 4407–4415, 2009. 
[27] S. Bleakley, R. H. Palmer, S. Bresina, S. P. Roca, and S. Tepic, “The effect of 
polydioxanone hemicerclage suture on the occurrence of fracture during tibial tuberosity 
advancement with an elongated bi-directional hinged osteotomy,” Vet. Surg., vol. 46, no. 
4, pp. 486–493, 2017. 
[28] A. Kendal, S. Snelling, S. Dakin, E. Stace, P. a. Mouthuy, and a. Carr, “Resorbable 
electrospun polydioxanone fibres modify the behaviour of cells from both healthy and 
diseased human tendons,” Eur. Cells Mater., vol. 33, pp. 169–182, 2017. 
[29] D. M. Wüst, D. C. Meyer, P. Favre, and C. Gerber, “Mechanical and Handling Properties 
of Braided Polyblend Polyethylene Sutures in Comparison to Braided Polyester and 
Monofilament Polydioxanone Sutures,” Arthrosc. - J. Arthrosc. Relat. Surg., vol. 22, no. 
11, pp. 1146–1153, 2006. 
[30] S. Fink, “The intraluminal pressures in the intact human intestine,” Gastroenterology, vol. 
36, no. 5, pp. 661–71, 1959. 
[31] T. Elzein, M. Nasser-Eddine, C. Delaite, S. Bistac, and P. Dumas, “FTIR study of 
polycaprolactone chain organization at interfaces,” J. Colloid Interface Sci., vol. 273, no. 
2, pp. 381–387, 2004. 
[32] N. Goonoo, A. Bhaw-Luximon, I. a. Rodriguez, G. L. Bowlin, and D. Jhurry, “Poly(ester-
ether)s: I. investigation of the properties of blend films of polydioxanone and poly(methyl 
dioxanone),” Int. J. Polym. Mater. Polym. Biomater., vol. 63, no. 10, pp. 527–537, 2014.  
 
